These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21868528)

  • 1. Interaction of radiation and pemetrexed on a human malignant mesothelioma cell line in vitro.
    Yoshida D; Ebara T; Sato Y; Kaminuma T; Takahashi T; Asao T; Nakano T
    Anticancer Res; 2011 Sep; 31(9):2847-51. PubMed ID: 21868528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
    Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
    Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
    Tamura K; Fujiwara Y
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):248-50. PubMed ID: 21114772
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
    Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
    J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
    O'Kane SL; Eagle GL; Greenman J; Lind MJ; Cawkwell L
    Lung Cancer; 2010 Feb; 67(2):160-5. PubMed ID: 19450893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
    Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation recall dermatitis with pemetrexed.
    Hureaux J; Le Guen Y; Tuchais C; Savary L; Urban T
    Lung Cancer; 2005 Nov; 50(2):255-8. PubMed ID: 16111784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
    J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma].
    Wang ZK; Hu Y; Zhao H; Fu C
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):978-80. PubMed ID: 20501373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of semiquantitative fluorescence imaging and PET tracer uptake in mesothelioma models as a monitoring system for growth and therapeutic effects.
    Saito Y; Furukawa T; Arano Y; Fujibayashi Y; Saga T
    Nucl Med Biol; 2008 Nov; 35(8):851-60. PubMed ID: 19026946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
    Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
    J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.